{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:48:38Z","timestamp":1792399718352,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s42358-019-0080-x","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T09:03:03Z","timestamp":1565168583000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":146,"title":["Benzbromarone in the treatment of gout"],"prefix":"10.1186","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2346-388X","authenticated-orcid":false,"given":"Valderilio Feij\u00f3","family":"Azevedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Age","family":"Kos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz","family":"Vargas-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldo","family":"da Rocha Castelar Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"dos Santos Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,7]]},"reference":[{"issue":"6","key":"80_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/ar3199","volume":"12","author":"E Roddy","year":"2010","unstructured":"Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther BioMed Central. 2010;12(6):223.","journal-title":"Arthritis Res Ther BioMed Central"},{"issue":"1","key":"80_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12325-014-0175-z","volume":"32","author":"F Perez-Ruiz","year":"2015","unstructured":"Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther Springer. 2015;32(1):31\u201341.","journal-title":"Adv Ther Springer"},{"issue":"1","key":"80_CR3","first-page":"123","volume":"15","author":"T Bardin","year":"2017","unstructured":"Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med BioMed Central. 2017;15(1):123.","journal-title":"BMC Med BioMed Central"},{"issue":"1","key":"80_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/annrheumdis-2014-206410","volume":"75","author":"C-F Kuo","year":"2016","unstructured":"Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis. 2016;75(1):210\u20137 BMJ Publishing Group.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"80_CR5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/RHU.0b013e31827d8790","volume":"19","author":"BN Cronstein","year":"2013","unstructured":"Cronstein BN, Sunkureddi P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol. 2013;19(1):19\u201329 NIH Public Access.","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"80_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.rbr.2016.06.009","volume":"57","author":"Valderilio Feij\u00f3 Azevedo","year":"2017","unstructured":"Azevedo VF, Lopes MP, Catholino NM, Dos E, Paiva S, Ara\u00fajo A, et al. Revis\u00e3o cr\u00edtica do tratamento medicamentoso da gota no Brasil critical revision of the medical treatment of gout in Brazil. Rev Bras Reumatol. 2017;57:346\u201355.","journal-title":"Revista Brasileira de Reumatologia"},{"key":"80_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1471-2369-15-122","volume":"15","author":"L Li","year":"2014","unstructured":"Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122 BioMed Central.","journal-title":"BMC Nephrol"},{"issue":"6","key":"80_CR8","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/eurheartj\/ehq473","volume":"32","author":"GS Filippatos","year":"2011","unstructured":"Filippatos GS, Ahmed MI, Gladden JD, Mujib M, Aban IB, Love TE, et al. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J. 2011;32(6):712\u201320 Oxford University Press.","journal-title":"Eur Heart J"},{"issue":"9","key":"80_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1136\/ard.57.9.545","volume":"57","author":"F Perez-Ruiz","year":"1998","unstructured":"Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garc\u00eda-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57(9):545\u20139 BMJ Publishing Group.","journal-title":"Ann Rheum Dis"},{"key":"80_CR10","unstructured":"Jansen TLTA, Reinders MK, van Roon EN, Brouwers JRBJ. Benzbromarone withdrawn from the European market: another case of &quot;absence of evidence is evidence of absence&quot;? Clin Exp Rheumatol. 22(5):651."},{"key":"80_CR11","unstructured":"Benzbromarone [Internet]. [cited 2018 May 24]. Available from: \n                    https:\/\/livertox.nlm.nih.gov\/Benzbromarone.htm\n                    \n                  ."},{"key":"80_CR12","unstructured":"Benzbromarone - \n                    Drugs.com\n                    \n                   [Internet]. [cited 2018 May 29]. Available from: \n                    https:\/\/www.drugs.com\/international\/benzbromarone.html"},{"issue":"4","key":"80_CR13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/hep.20634","volume":"41","author":"P Kaufmann","year":"2005","unstructured":"Kaufmann P, T\u00f6r\u00f6k M, H\u00e4nni A, Roberts P, Gasser R, Kr\u00e4henb\u00fchl S. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology. 2005;41(4):925\u201335 Wiley-Blackwell.","journal-title":"Hepatology"},{"issue":"6887","key":"80_CR14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nature742","volume":"417","author":"A Enomoto","year":"2002","unstructured":"Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Ho Cha S, et al. Molecular identification of a renal urate\u2013anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447\u201352.","journal-title":"Nature."},{"issue":"20","key":"80_CR15","first-page":"701","volume":"59","author":"A Masbernard","year":"1981","unstructured":"Masbernard A, Giudicelli CP. Ten years\u2019 experience with benzbromarone in the management of gout and hyperuricaemia. S Afr Med J. 1981;59(20):701\u20136.","journal-title":"S Afr Med J"},{"issue":"8","key":"80_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","volume":"31","author":"M-HH Lee","year":"2008","unstructured":"Lee M-HH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31(8):643\u201365.","journal-title":"Drug Saf"},{"issue":"11","key":"80_CR17","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/BF00185609","volume":"71","author":"JX Vries","year":"1993","unstructured":"Vries JX, Walter-Sack I, Ittensohn A, Weber E, Empl H, Gresser U, et al. Benzbromarone hydroxylation in man: defective formation of the 6-hydroxybenzbromarone metabolite. Clin Investig. 1993;71(11):947\u201352 Springer-Verlag.","journal-title":"Clin Investig"},{"issue":"2","key":"80_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/art.1780170207","volume":"17","author":"Adesh K. Jain","year":"1974","unstructured":"Jain AK, Ryan JR, McMahon FG, Noveck RJ. Effect of single oral doses of benzbromarone on serum and urinary uric acid. Arthritis Rheum. 17(2):149\u201357.","journal-title":"Arthritis & Rheumatism"},{"issue":"9","key":"80_CR19","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/imj.13173","volume":"46","author":"LK Stamp","year":"2016","unstructured":"Stamp LK, Haslett J, Frampton C, White D, Gardner D, Stebbings S, et al. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand. Intern Med J. 2016;46(9):1075\u201380.","journal-title":"Intern Med J"},{"issue":"1","key":"80_CR20","doi-asserted-by":"publisher","first-page":"33082","DOI":"10.1038\/srep33082","volume":"6","author":"S Li","year":"2016","unstructured":"Li S, Yang H, Guo Y, Wei F, Yang X, Li D, et al. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. Sci Rep. 2016;6(1):33082.","journal-title":"Sci Rep"},{"issue":"02","key":"80_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5414\/CP202629","volume":"55","author":"Q Zhou","year":"2017","unstructured":"Zhou Q, Su J, Zhou T, Tian J, Chen J, Zhu J. A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study. Int J Clin Pharmacol Ther. 2017;55(02):163\u20138.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"80_CR22","first-page":"84","volume":"28","author":"Y Moriwaki","year":"1990","unstructured":"Moriwaki Y, Yamamoto T, Takahashi S, Hada T, Higashino K. Analysis of uric acid transport in renal tubules using benzbromarone and pyrazinamide. Int J Clin Pharmacol Ther Toxicol. 1990;28(2):84\u20138.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"80_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-1-4615-9140-5_46","volume":"122A","author":"R Bluestone","year":"1980","unstructured":"Bluestone R, Klinenberg J, Lee IK. Benzbromarone as a long-term uricosuric agent. Adv Exp Med Biol. 1980;122A:283\u20136.","journal-title":"Adv Exp Med Biol"},{"issue":"Suppl 1","key":"80_CR24","first-page":"S40","volume":"85","author":"P Hanvivadhanakul","year":"2002","unstructured":"Hanvivadhanakul P, Akkasilpa S, Deesomchok U. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients. J Med Assoc Thail. 2002;85(Suppl 1):S40\u20137.","journal-title":"J Med Assoc Thail"},{"issue":"2","key":"80_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00124743-199904000-00003","volume":"5","author":"F Perez-Ruiz","year":"1999","unstructured":"Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erauskin G, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol. 1999;5(2):49\u201355.","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"80_CR26","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1136\/ard.2008.091462","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, Haagsma C, Jansen TLTA, van Roon EN, Delsing J, van de Laar MAFJ, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg\/day versus benzbromarone 100-200 mg\/day in patients with gout. Ann Rheum Dis. 2009;68(6):892\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"80_CR27","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/art.10511","volume":"47","author":"F Perez-Ruiz","year":"2002","unstructured":"Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47(4):356\u201360.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"80_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/ard.2007.083071","volume":"68","author":"MK Reinders","year":"2008","unstructured":"Reinders MK, van Roon EN, Jansen TLTA, Delsing J, Griep EN, Hoekstra M, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2008;68(1):51\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"1217","key":"80_CR29","first-page":"U1528","volume":"118","author":"S Kumar","year":"2005","unstructured":"Kumar S, Ng J, Gow P. Benzbromarone therapy in management of refractory gout. N Z Med J. 2005;118(1217):U1528.","journal-title":"N Z Med J"},{"key":"80_CR30","doi-asserted-by":"publisher","first-page":"263720","DOI":"10.1155\/2014\/263720","volume":"2014","author":"VF Azevedo","year":"2014","unstructured":"Azevedo VF, Buiar PG, Giovanella LH, Severo CR, Carvalho M. Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients. Int J Rheumatol. 2014;2014:263720.","journal-title":"Int J Rheumatol"},{"issue":"9","key":"80_CR31","first-page":"1620","volume":"33","author":"H-W Chou","year":"2017","unstructured":"Chou H-W, Chiu H-T, Tsai C-W, Ting I-W, Yeh H-C, Huang H-C, et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant. 2017;33(9):1620\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"80_CR32","first-page":"421","volume":"98","author":"T Suzuki","year":"2001","unstructured":"Suzuki T, Suzuki T, Kimura M, Shinoda M, Fujita T, Miyake N, et al. A case of fulminant hepatitis, possibly caused by benzbromarone. Nihon Shokakibyo Gakkai Zasshi. 2001;98(4):421\u20135.","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"issue":"5","key":"80_CR33","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S0168-8278(00)80263-9","volume":"32","author":"H Wagayama","year":"2000","unstructured":"Wagayama H, Shiraki K, Sugimoto K, Fujikawa K, Shimizu A, Takase K, et al. Fatal fulminant hepatic failure associated with benzbromarone. J Hepatol. 2000;32(5):874.","journal-title":"J Hepatol"},{"issue":"3","key":"80_CR34","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S0168-8278(94)80011-1","volume":"20","author":"MM van der Klauw","year":"1994","unstructured":"van der Klauw MM, Houtman PM, Stricker BHC, Spoelstra P. Hepatic injury caused by benzbromarone. J Hepatol. 1994;20(3):376\u20139.","journal-title":"J Hepatol"},{"issue":"5","key":"80_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1046\/j.1440-1746.2002.02692.x","volume":"17","author":"M Arai","year":"2002","unstructured":"Arai M, Yokosuka O, Fujiwara K, Kojima H, Kanda T, Hirasawa H, et al. Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol. 2002;17(5):625\u20136.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"80_CR36","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12328-016-0648-5","volume":"9","author":"J Kumagai","year":"2016","unstructured":"Kumagai J, Kanda T, Yasui S, Haga Y, Sasaki R, Nakamura M, et al. Autoimmune hepatitis following drug-induced liver injury in an elderly patient. Clin J Gastroenterol. 2016;9(3):156\u20139.","journal-title":"Clin J Gastroenterol"},{"key":"80_CR37","doi-asserted-by":"crossref","unstructured":"Yu H, Liu X, Song Y, Cheng J, Bao H, Qin L, et al. Safety and efficacy of Benzbromarone and Febuxostat in hyperuricemia patients with chronic kidney disease: a prospective pilot study. Clin Exp Nephrol. 2018;14.","DOI":"10.1007\/s10157-018-1586-y"},{"issue":"7","key":"80_CR38","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00296-014-3189-6","volume":"35","author":"I Castrejon","year":"2015","unstructured":"Castrejon I, Toledano E, Rosario MP, Loza E, P\u00e9rez-Ruiz F, Carmona L. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis. Rheumatol Int. 2015;35(7):1127\u201337.","journal-title":"Rheumatol Int"},{"key":"80_CR39","first-page":"CD010457","volume":"11","author":"AS Kydd","year":"2014","unstructured":"Kydd AS, Seth R, Buchbinder R, Edwards CJ, Bombardier C. Uricosuric medications for chronic gout. Cochrane Database Syst Rev. 2014;11:CD010457.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"80_CR40","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.1840090504","volume":"9","author":"JH Lewis","year":"1989","unstructured":"Lewis JH, Ranard RC, Caruso A, Jackson LK, Mullick F, Ishak KG, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology. 1989;9(5):679\u201385.","journal-title":"Hepatology."},{"key":"80_CR41","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tox.2014.08.002","volume":"324","author":"A Felser","year":"2014","unstructured":"Felser A, Lindinger PW, Schnell D, Kratschmar DV, Odermatt A, Mies S, et al. Hepatocellular toxicity of benzbromarone: effects on mitochondrial function and structure. Toxicology. 2014;324:136\u201346.","journal-title":"Toxicology."},{"issue":"3","key":"80_CR42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2133\/dmpk.DMPK-12-NT-105","volume":"28","author":"K Kobayashi","year":"2013","unstructured":"Kobayashi K, Kajiwara E, Ishikawa M, Mimura H, Oka H, Ejiri Y, et al. Cytotoxic effects of Benzbromarone and its 1\u2032-Hydroxy metabolite in human Hepatocarcinoma FLC4 cells cultured on micro-space cell culture plates. Drug Metab Pharmacokinet. 2013;28(3):265\u20138.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"12","key":"80_CR43","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1021\/tx7001228","volume":"20","author":"MG McDonald","year":"2007","unstructured":"McDonald MG, Rettie AE. Sequential metabolism and bioactivation of the Hepatotoxin Benzbromarone: formation of glutathione adducts from a catechol intermediate. Chem Res Toxicol. 2007;20(12):1833\u201342.","journal-title":"Chem Res Toxicol"},{"issue":"4","key":"80_CR44","first-page":"607","volume":"44","author":"K Wang","year":"2016","unstructured":"Wang K, Wang H, Peng Y, Zheng J. Identification of Epoxide-Derived Metabolite(s) of Benzbromarone. Drug Metab Dispos. Am Soc Pharmacol Exp Ther. 2016;44(4):607\u201315.","journal-title":"Am Soc Pharmacol Exp Ther"},{"issue":"12","key":"80_CR45","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1021\/acs.chemrestox.6b00275","volume":"29","author":"H Wang","year":"2016","unstructured":"Wang H, Feng Y, Wang Q, Guo X, Huang W, Peng Y, et al. Cysteine-based protein adduction by epoxide-derived metabolite(s) of Benzbromarone. Chem Res Toxicol American Chemical Soc. 2016;29(12):2145\u201352.","journal-title":"Chem Res Toxicol American Chemical Soc"},{"issue":"12","key":"80_CR46","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1124\/dmd.117.077818","volume":"45","author":"H Wang","year":"2017","unstructured":"Wang H, Peng Y, Zhang T, Lan Q, Zhao H, Wang W, et al. Metabolic epoxidation is a critical step for the development of Benzbromarone-induced hepatotoxicity. Drug Metab Dispos. 2017;45(12):1354\u201363.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"80_CR47","doi-asserted-by":"publisher","first-page":"e21946","DOI":"10.1002\/jbt.21946","volume":"31","author":"M Yoshida","year":"2017","unstructured":"Yoshida M, Cho N, Akita H, Kobayashi K. Association of a reactive intermediate derived from 1\u2032,6-dihydroxy metabolite with benzbromarone-induced hepatotoxicity. J Biochem Mol Toxicol. 2017;31(10):e21946.","journal-title":"J Biochem Mol Toxicol"},{"issue":"9","key":"80_CR48","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1124\/dmd.115.065037","volume":"43","author":"Y Kitagawara","year":"2015","unstructured":"Kitagawara Y, Ohe T, Tachibana K, Takahashi K, Nakamura S, Mashino T. Novel bioactivation pathway of Benzbromarone mediated by cytochrome P450. Drug Metab Dispos. 2015;43(9):1303\u20136.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"80_CR49","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0041-008X(90)90345-U","volume":"106","author":"N Bichet","year":"1990","unstructured":"Bichet N, Cahard D, Fabre G, Remandet B, Gouy D, Cano J-P. Toxicological studies on a benzofuran derivative: III. Comparison of peroxisome proliferation in rat and human hepatocytes in primary culture. Toxicol Appl Pharmacol. 1990;106(3):509\u201317 Academic Press.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"80_CR50","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/0041-008X(90)90343-S","volume":"106","author":"W Parzefall","year":"1990","unstructured":"Parzefall W, Schuppler J, Barthel G, Meyer-Rogge B, Schulte-Hermann R. Toxicological studies on a benzofurane derivative: I. A comparative study with phenobarbital on rat liver. Toxicol Appl Pharmacol. 1990;106(3):482\u201399 Academic Press.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"80_CR51","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/0041-008X(90)90344-T","volume":"106","author":"EG Butler","year":"1990","unstructured":"Butler EG, Ichida T, Maruyama H, Schulte-Hermann R, Williams GM. Toxicological studies on a benzofurane derivative: II. Demonstration of peroxisome proliferation in rat liver. Toxicol Appl Pharmacol. 1990;106(3):500\u20138 Academic Press.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"80_CR52","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/j.bbadis.2018.03.009","volume":"1864","author":"P Sun","year":"2018","unstructured":"Sun P, Zhu J-J, Wang T, Huang Q, Zhou Y-R, Yu B-W, et al. Benzbromarone aggravates hepatic steatosis in obese individuals. Biochim Biophys Acta Mol Basis Dis. 2018;1864(6):2067\u201377.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"80_CR53","doi-asserted-by":"crossref","unstructured":"Fornasier G, Taborelli M, Francescon S, Polesel J, Aliberti M, De Paoli P, et al. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance. Int J Clin Pharm. 2018;21.","DOI":"10.1007\/s11096-018-0653-5"},{"issue":"10","key":"80_CR54","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"80_CR55","first-page":"16","volume":"1","author":"I Walter-Sack","year":"1995","unstructured":"Walter-Sack I, de Vries JX, von Bubnoff A, Pfleilschifter V, Raedsch R. Biotransformation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis - evidence for active benzbromarone metabolites? Eur J Med Res. 1995;1(1):16\u201320.","journal-title":"Eur J Med Res"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-019-0080-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s42358-019-0080-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-019-0080-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T19:36:46Z","timestamp":1596656206000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-019-0080-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,7]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["80"],"URL":"https:\/\/doi.org\/10.1186\/s42358-019-0080-x","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,7]]},"assertion":[{"value":"27 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Valderilio Azevedo: has received grant and speaker fees from AbbVie and Pfizer, speaker fees from UCB, Janssen, BMS, and advisory board fees from Pfizer.Geraldo da Rocha Castelar Pinheiro: Has received consulting fees from Gr\u00fcnenthal.Ana Beatriz Vargas-Santos has received speaking fee (USD <\u20091,000.00) and supporting for international medical events from Gr\u00fcnenthal.The other authors declare to have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}